VIOLIN: Vaccine Investigation and Online Information Network

Vaccine Detail

Recombinant Vaccinia-Multiepitope Melanoma Peptides-B7.1-B7.2 Vaccine

Vaccine Information

Vaccine Name: Recombinant Vaccinia-Multiepitope Melanoma Peptides-B7.1-B7.2 Vaccine
Target Pathogen: Cancer
Target Disease: Cancer
Vaccine Ontology ID: VO_0007105
Type: Recombinant vector vaccine
Status: Clinical trial
Host Species for Licensed Use: Human
Host Species as Laboratory Animal Model: Human
Antigen: gp100, MLANA, tyrosinase, CD80, CD86
Cd86 gene engineering:
- Type: Recombinant protein preparation
- Description: (Guo et al., 2019)
- Detailed Gene Information: Click Here.
MLANA-Dupli gene engineering:
- Type: Recombinant protein preparation
- Description: (Guo et al., 2019)
- Detailed Gene Information: Click Here.
CD80 gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
gp100 (PMEL) gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
Preparation: Vaccinia virus vector coordinately expressing multiple antigen epitopes and two co-stimulatory molecules B7.1 and B7.2 was injected in the context of systemic GM-CSF (Guo et al., 2019).
Description: This is for Melanoma Cancer. A cancer vaccine consisting of an inactivated recombinant vaccinia virus encoding epitope peptides derived from melanoma-related HLA-A2-restricted tumor-associated antigens (TAAs), including Melan-A(27-35), gp100(280-288) and tyrosinase(1-9), and two co-stimulatory B7 proteins, B7.1 (CD80) and B7.2 (CD86). Upon administration, recombinant vaccinia-multiepitope melanoma peptides-B7.1-B7.2 vaccine may stimulate a cytotoxic T-lymphocyte response against melanoma cells that express TAAs which share epitopes with the epitope peptides expressed by the vaccine viral vector, resulting in tumor cell lysis; vaccine viral vector-expressed co-stimulatory proteins B7.1 and B7.2 may enhance the cytotoxic T-lymphocyte immune response to the TAAs (NCIT_C48638).

Host Response

References

Guo et al., 2019: Guo ZS, Lu B, Guo Z, Giehl E, Feist M, Dai E, Liu W, Storkus WJ, He Y, Liu Z, Bartlett DL. Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics. Journal for immunotherapy of cancer. 2019; 7(1); 6. [PubMed: 30626434].

NCIT_C48638: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48638]